Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions-Reference-Cited by-同舟云学术

Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions

Published:2017-08-03 Issue: Volume:7 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Wein Lironne,Savas Peter,Luen Stephen J.,Virassamy Balaji,Salgado Roberto,Loi Sherene

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference59 articles.

1. Cancer immunoediting: from immunosurveillance to tumor escape;Dunn;Nat Immunol,2002

2. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape;Mittal;Curr Opin Immunol,2014

3. Tumor-infiltrating lymphocytes and breast cancer: beyond the prognostic and predictive utility;Ravelli;Tumour Biol,2017

4. Tumor-infiltrating lymphocytes: a promising biomarker in breast cancer;Ingold Heppner;Breast Care (Basel),2016

5. Relevance of tumor-infiltrating lymphocytes in breast cancer;Dushyanthen;BMC Med,2015

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Annotation-efficient deep learning for breast cancer whole-slide image classification using tumour infiltrating lymphocytes and slide-level labels;Communications Engineering;2024-07-25

2. Detailed Profiling of the Tumor Microenvironment in Ethnic Breast Cancer, Using Tissue Microarrays and Multiplex Immunofluorescence;International Journal of Molecular Sciences;2024-06-13

3. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting;Annals of Diagnostic Pathology;2024-06

4. Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting;The Prostate;2024-04-29

5. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR);Histopathology;2024-03-05